rsid,gene,trait,impact
rs1057910,CYP2C9,Warfarin metabolism,Reduced clearance
rs1799853,CYP2C9,NSAID metabolism,Impaired enzyme activity
rs9923231,VKORC1,Warfarin sensitivity,Lower dose requirement
rs4149056,SLCO1B1,Statin-induced myopathy,Higher risk with simvastatin
rs3892097,CYP2D6,Codeine metabolism,Poor metabolizer
rs5030655,CYP2D6,Tramadol metabolism,Altered analgesic response
rs1065852,CYP2D6,Fluoxetine metabolism,Reduced enzyme activity
rs4244285,CYP2C19,Clopidogrel activation,Loss-of-function allele
rs12248560,CYP2C19,Clopidogrel activation,Gain-of-function allele
rs776746,CYP3A5,Tacrolimus metabolism,High dose requirement
rs2647087,TPMT,Azathioprine metabolism,Low enzymatic activity
rs1800460,TPMT,6-MP toxicity,Intermediate metabolizer
rs1142345,TPMT,Thiopurine response,Deficient enzyme variant
rs1801133,MTHFR,Methotrexate sensitivity,Altered folate cycle
rs1801394,MTRR,Folate recycling,Impact on methylation pathway
rs116855232,HLA-B,Abacavir hypersensitivity,High risk allele
rs9264942,HLA-B,Hypersensitivity,Linked to adverse drug reaction
rs1041983,NAT2,Isoniazid metabolism,Slow acetylator
rs1801280,NAT2,Hydralazine response,Slow acetylation risk
rs1799930,NAT2,Sulfonamide toxicity,Reduced metabolism
rs3093105,G6PD,Antimalarial drug safety,Hemolysis risk
rs1803274,BCHE,Succinylcholine metabolism,Prolonged apnea
rs1051266,SLC19A1,Methotrexate transport,Decreased folate influx
rs4149117,SLCO1B3,Statin handling,Altered hepatic uptake
rs1800900,DPYD,5-FU toxicity,Deficient DPD activity
rs3918290,DPYD,Fluoropyrimidine toxicity,Severe reaction risk
rs67376798,DPYD,Chemotherapy metabolism,Reduced clearance
rs72552713,DPYD,Capecitabine toxicity,Non-functional variant
rs2231142,ABCG2,Allopurinol response,Gout and transporter function
rs1056827,CYP1B1,Estrogen metabolism,Increased hormone turnover
rs12777823,CYP2C9,Warfarin sensitivity,Dose adjustment needed
rs3093105,G6PD,Dapsone safety,Hemolysis sensitivity
rs1051298,SLC19A1,Leucovorin transport,Altered efficacy
rs7439366,UGT1A1,Irinotecan toxicity,Decreased glucuronidation
rs887829,UGT1A1,Bilirubin metabolism,Risk of Gilbert syndrome
rs8175347,UGT1A1,Irinotecan clearance,Reduced enzymatic function
rs1799971,OPRM1,Opioid sensitivity,Altered analgesic response
rs6265,BDNF,Antidepressant response,Variable SSRI efficacy
rs74315329,CYP2A6,Nicotine metabolism,Slow metabolizer variant
rs2032582,ABCB1,Drug efflux transporter,Altered absorption
rs1045642,ABCB1,Multidrug resistance,Decreased bioavailability
rs1128503,ABCB1,Chemotherapy transport,Impaired efflux
rs1800497,ANKK1,Antipsychotic response,Dopaminergic sensitivity
rs4680,COMT,Catecholamine metabolism,Neuropsychiatric drug impact
rs28399504,CYP2B6,Efavirenz metabolism,Neurotoxicity risk
rs3745274,CYP2B6,Methadone metabolism,Slower clearance
rs2279343,CYP2B6,Cyclophosphamide toxicity,Metabolism variant
rs1800440,CYP3A4,Drug clearance,Reduced expression allele
rs4646437,CYP3A4,Drug metabolism variability,Functional impact
rs72558181,CYP2C9,Warfarin metabolism,Low activity
rs56165452,CYP2C19,Omeprazole metabolism,Increased AUC
rs28399433,CYP2A6,Metabolism of coumarins,Increased clearance
rs2228001,XPC,Cisplatin toxicity,Enhanced DNA damage
rs3135506,APOA5,Statin efficacy,Lipid lowering response
rs1805124,SCN5A,Drug-induced arrhythmia,Cardiac conduction variant
rs4880,SOD2,Doxorubicin cardiotoxicity,Oxidative stress risk
rs2070744,NOS3,Anti-hypertensive response,Nitric oxide synthesis
rs1799854,CYP2D6,Metoprolol metabolism,Beta-blocker clearance
rs4148323,UGT1A1,Atazanavir metabolism,Higher bilirubin levels
rs4149056,SLCO1B1,Rosuvastatin clearance,Muscle toxicity risk
rs1042713,ADRB2,Asthma drug response,Beta-agonist sensitivity
rs1801253,ADRB1,Beta-blocker efficacy,Heart rate modulation
rs1048943,CYP1A1,Polycyclic metabolism,Environmental drug interactions
rs1051740,EPHX1,Carcinogen metabolism,Reduced enzyme activity
rs1799811,CYP1A2,Caffeine/drug interaction,Clearance rate impact
rs28371725,CYP2C9,Phenytoin metabolism,Toxicity risk
rs1799853,CYP2C9,NSAID risk,GI bleed susceptibility
rs1058930,CYP2A6,Nicotine patch metabolism,Personalized cessation
rs16947,CYP2D6,SSRI metabolism,Intermediate function allele
rs28371706,CYP2D6,Codeine efficacy,Ultra-rapid metabolizer
rs1135840,CYP2D6,Drug metabolism,Enzyme variant
rs5030865,CYP2C19,Proton pump inhibitor metabolism,Loss-of-function
rs4244285,CYP2C19,Benzodiazepine metabolism,Increased exposure
rs3758581,CYP2B6,Antiviral clearance,Efavirenz neurotoxicity
rs1142345,TPMT,Azathioprine tolerance,Toxic metabolite buildup
rs1800462,NUDT15,Thiopurine toxicity,Asian-specific variant
rs116855232,HLA-B,Allopurinol hypersensitivity,Severe skin reaction
rs115232898,HLA-B,Flucloxacillin DILI risk,Hepatotoxicity susceptibility
rs1015164,HCP5,Nevirapine toxicity,Hypersensitivity syndrome
rs2395029,HLA-B,Drug-induced rash,Immunologic reaction
rs28371725,CYP2C9,Phenytoin metabolism,Slow clearance
rs1799943,CYP3A5,Cyclosporine handling,Impaired metabolism
rs7787082,CYP3A5,Drug transporter,Allelic variation
rs1041981,LTA,Infliximab response,Cytokine modulation
rs1801131,MTHFR,Antifolate response,Reduced enzyme function
rs1801133,MTHFR,Trimethoprim-sulfamethoxazole response,Folate-related toxicity
rs1080985,CYP2D6,Tramadol clearance,Enzyme polymorphism
rs28399499,CYP2C9,Phenytoin metabolism,High toxicity risk
rs1208,NAT2,Isoniazid clearance,Fast acetylator
rs1800629,TNF,Thalidomide response,Cytokine regulation
rs2236225,MTHFD1,Folate-based drugs,Impaired conversion
rs429358,APOE,Cholesterol drug response,Statin impact variation
rs2740574,CYP3A4,Drug metabolism,Enzyme induction
rs8187710,UGT1A6,Paracetamol metabolism,Altered clearance
rs1799946,CYP3A5,Tacrolimus response,Reduced exposure
rs28399433,CYP2A6,Metabolism,Anti-smoking drug impact
rs5031016,CYP2D6,Oxycodone metabolism,Ultrarapid metabolizer
rs1065852,CYP2D6,Antidepressants metabolism,Enzyme deficiency
rs1800975,XRCC1,Cisplatin toxicity,Reduced DNA repair
rs2072671,DPYD,Chemotherapy,Reduced clearance
rs1799931,NAT2,Hydralazine metabolism,Susceptibility to lupus
rs776746,CYP3A5,FK506 metabolism,Variable AUC
rs1801133,MTHFR,Drug sensitivity,Impaired methylation
rs1135840,CYP2D6,Mirtazapine metabolism,Altered sedation profile
rs5758550,CYP2C9,NSAID response,Ultrarapid metabolism
rs6413432,ADRB1,Metoprolol sensitivity,Beta-1 blocker efficacy
rs2228000,XRCC1,Cisplatin-induced damage,Increased toxicity
rs4148326,UGT1A1,Atazanavir-induced hyperbilirubinemia,Low clearance
rs1051296,ABCB1,P-glycoprotein activity,Drug absorption variability
rs6088659,CYP3A5,Cyclosporine pharmacokinetics,Reduced activity
rs738409,PNPLA3,Statin-related liver effects,Elevated ALT risk
rs1063320,HLA-DQA1,Immunotherapy response,Adverse reaction potential
rs1135840,CYP2D6,Drug interaction risk,Enzyme variability
rs1800497,ANKK1,Antipsychotic metabolism,D2 receptor association
rs1042713,ADRB2,Inhaled Î²2 agonists,Response variance
rs1048943,CYP1A1,Polycyclic hydrocarbon detox,Enzyme efficiency
rs2735383,ABCG2,Multidrug resistance protein,Efflux modulation
rs2231142,ABCG2,Gout and drug clearance,Altered urate transporter
rs2032582,ABCB1,Doxorubicin clearance,Efflux activity
rs1051740,EPHX1,Drug activation phase I,Impact on prodrugs
rs1169288,HNF1A,Statin metabolism,Gene expression regulator
rs1800566,NQO1,Antioxidant drug metabolism,Reduced function
rs8187710,UGT1A1,Acetaminophen response,Low clearance
rs2072671,DPYD,Cancer drug toxicity,Low enzyme activity
rs3814055,ABCA1,Statin-induced myopathy,Risk allele
rs1799853,CYP2C9,Diclofenac metabolism,Low activity allele
rs11692055,SULT1A1,Drug sulfonation,Metabolic variation
rs17222723,CYP2C8,Repaglinide metabolism,Clearance variability
rs578776,CHRNA5,Nicotine metabolism,Addiction medication response
rs1135840,CYP2D6,Drug clearance variability,Dose adjustment allele